医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

USANA Announces Plans to Open Indonesia Market

2015年04月15日 PM10:29
このエントリーをはてなブックマークに追加


 

SALT LAKE CITY

As the direct selling industry continues to boom around the world, USANA Health Sciences, a global nutritional company, today announced that it will commence operations in Indonesia later this year. Headquartered in the Jarkarta Central Business District, USANA’s presence in Indonesia will mark USANA’s 20th market worldwide.

“As we continue to build USANA’s global brand, we’re thrilled to open our doors in Indonesia,” said USANA President, Kevin Guest. “International growth is important to the vision of USANA, and we look forward to offering our Associates the opportunity to build in this promising market.”

Direct Selling in Indonesia

  • Broke into the Direct Selling’s Billion Dollar Market in 2011, with $1 billion in total sales and 10 percent total sales growth over 2010 statistics
  • Estimated 8.3 million residents are direct sellers
  • Fourth most populous country in the world
  • Fifth fastest growing economy – middle class expected to double in next five years

USANA will launch with its flagship product, the Essentials™, along with several of its key optimizers. The state-of-the-art building in Jakarta will house employee offices, a will-call center, a distributor meeting area and several large meeting rooms.

For more information about USANA’s products and company, visit USANA.com.

About USANA

Founded in 1992, USANA Health Sciences (NYSE: USNA) is a U.S.-based nutritional company that manufactures high-quality supplements, personal care and energy products in its FDA-registered facility in Salt Lake City. Learn more about USANA by visiting our web site http://www.usana.com or the official USANA blog http://whatsupusana.com.

CONTACT

USANA Health Sciences, Inc.
Ashley Collins, 801-954-7629
Executive
Director of Public Relations and Social Media
media(at)us.usana(dot)com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent